List view / Grid view
15 October 2014 | By Seahorse Bioscience
Seahorse Bioscience and the University of Alabama at Birmingham announced that they have entered into a partnership to study the bioenergetic health of cells in cryo-preserved blood – a step that will ultimately produce a first-of-its-kind clinical test of metabolic bioenergetic health...
15 October 2014 | By Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
14 October 2014 | By Imaxio
Imaxio announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg...
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
13 October 2014 | By Horizon Discovery Group
Horizon Discovery Group plc announced it has agreed to acquire Sage Labs Inc. (Sage) for up to $16M (£9.8M) in cash and up to $32M (£19.6M) through the issue of new ordinary shares...
10 October 2014 | By Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. has been awarded a two-year, $1.4 million grant from National Cancer Institute under its SBIR Phase II Program...
9 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab)...
9 October 2014 | By On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the…
8 October 2014 | By Bristol-Myers Squibb Company
Studies will evaluate Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Novartis’ Zykadia (ceritinib), INC280 and EGF816...
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
3 October 2014 | By OBN
OBN revealed last night the winners of its Annual Awards celebrating the best of UK life sciences – the innovators, fundraisers and dealmakers who underline the pre-eminence of the UK sector in the global marketplace...
3 October 2014 | By GTCbio
From 7-10 October 2014, GTCbio will proudly present its Drug Discovery Week Europe event in the beautiful city of Dublin, Ireland...
3 October 2014 | By Allied-Bristol Life Sciences
Allied-Bristol Life Sciences today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company’s efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions...
